Barclays analyst Etzer Darout raised the firm’s price target on Terns Pharmaceuticals (TERN) to $56 from $36 and keeps an Overweight rating on the shares. The TERN-701 update supports the stock’s valuation update and shows a potential best-in-class” efficacy and safety profile, the analyst tells investors in a research note. The firm says treatment duration is still an important lever that longer term follow up will help refine.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Promising Potential of TERN-701: A Strong Contender in the CML Treatment Landscape
- Terns Pharmaceuticals Unveils Promising Phase 1 Trial Data
- Terns Parmaceuticles trading resumes
- Terns jumps 40% after announcing Phase 1 data for TERN-701
- Terns CEO says ‘delighted’ by ‘unprecedented’ Phase 1 data for TERN-701